NIH-Funded Trial Reshapes ICU Recovery Research With Surprising Findings

A landmark study funded by the National Institutes of Health has upended assumptions about how to help critically ill patients recover. Researchers at Johns Hopkins and eight other academic medical centers spent years testing a straightforward idea: what if you combined early exercise with extra protein while patients were still in the ICU? The theory was sound. Muscle wasting and weakness plague survivors of acute respiratory failure long after they leave the hospital. For more than a decade, critical care specialists had identified this combination—in-bed cycling paired with nutritional supplementation—as the most promising avenue to prevent that decline. So they built a rigorous trial to test it.

The Nutrition and Exercise in Critical Illness trial, or NEXIS, enrolled 115 patients across nine hospitals and had them either receive the combined intervention or standard ICU care. Researchers tracked not just survival but the things that matter most to people who've been through critical illness: how strong they became, how far they could walk, their quality of life, their thinking and memory. The study was published July 13 in the American Journal of Respiratory and Critical Care Medicine, and the findings surprised many in the field. The combined intervention was safe to deliver. Patients tolerated it. But it did not improve recovery compared to usual care.

This is the kind of result that stings at first but ultimately redirects science toward truth. "Recovery from critical illness is complex and advancing medical care requires rigorous research that challenges assumptions," said Dale Needham, the Johns Hopkins pulmonary and critical care physician who led the study. The trial did not fail because the researchers were careless. It succeeded because they asked the right question and accepted an answer that contradicted their hypothesis.

The stakes are real. Acute respiratory failure is one of the most common reasons adults end up in intensive care. Survival rates have improved over the years, but the cost to survivors is often invisible to those who haven't lived it. Many experience profound and lasting declines in physical function—weakness that can persist for months or years after discharge. Some never fully regain what they lost. Identifying interventions that reverse or prevent that trajectory has become a central focus of critical care research worldwide.

What makes NEXIS valuable is not that it proved the intervention works, but that it proved something else: the field needs to look elsewhere. Researchers noted that substantial physical impairment was common in both groups, underscoring how much work remains. They identified new priorities for investigation. One is anabolic resistance—a biological phenomenon in which the body struggles to use supplemental protein effectively during the early stages of critical illness. Another is understanding why recovery looks so different from patient to patient. Some people bounce back. Others don't. Why?

This is where the real work begins. The trial provides what Needham called "a stronger foundation for the next generation of rehabilitation and nutrition research." Johns Hopkins has spent more than two decades studying the long-term effects of critical illness and pioneering new models of ICU rehabilitation. The NEXIS study adds to that legacy not by confirming what researchers hoped but by clarifying what they still need to know. The goal, Needham said, is to identify the right interventions for the right patients at the right time. That precision—matching treatment to individual need—may be where recovery research heads next.